Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome

NACompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Nephrotic Syndrome in Children
Interventions
DRUG

Rituximab

"* Dosage: 375 mg/m²~* Route: Intravenous infusion~* Frequency: Once a week~* Duration: 12 consecutive weeks~* Details: Diluted in 5% glucose solution. Infusion started at 25 ml/h, increased by 25 ml/h every 30 minutes if no adverse reactions, up to 100-150 ml/h."

BEHAVIORAL

Targeted Nursing Care

A structured, individualized nursing approach involving joint goal-setting. Included health education, psychological support, relaxation techniques, dietary care, lifestyle guidance, complication management, and medication guidance. Delivered throughout hospital stay and reinforced during monthly follow-ups.

DRUG

Baseline Glucocorticoid Therapy

Patients already on maintenance glucocorticoids continued their regimen. For relapse at admission, IV methylprednisolone (2 mg/kg/day), then oral prednisone (2 mg/kg/day, max 60mg/day) tapered according to standard protocols.

DRUG

Tacrolimus

"* Dosage: Initial dose 0.05-0.1 mg/kg/day, adjusted to maintain target trough levels of 5-10 ng/mL.~* Route: Oral~* Frequency: Divided into two doses (morning and evening)~* Duration: Throughout the 6-month study period."

Trial Locations (1)

430015

Wuhan Children's Hospital, Wuhan

All Listed Sponsors
lead

Wuhan Children's Hospital

OTHER

NCT07049172 - Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome | Biotech Hunter | Biotech Hunter